In such settings, low levels of RGC-32 seem to indicate a protective, antifibrotic function of RGC-32 in the ischemia-damaged myocardium, whereas in stable chronic disease, RGC-32 serum values correlate with the extent of atherosclerotic lesions, advocating for a pro-atherogenic role of RGC-32. Here, RGCC is linked to ischemia.